Survodutide: doses reported in published research

Sources checked 2026-10-07 · 3 cited studies (3 human, 0 animal, 0 cell culture)

Survodutide (BI 456906) is an investigational dual glucagon and GLP-1 receptor agonist. It is not approved by the FDA; doses below come from published phase 2 trials.

Human data: published phase 2 trials (obesity, type 2 diabetes, MASH).

Studies in people (3)

Human 386 adults aged 18-75 with BMI 27 or more, without diabetes; phase 2 dose-finding randomized double-blind placebo-controlled trial

Dose as reported: 0.6, 2.4, 3.6 or 4.8 mg (separate groups)
Route: Subcutaneous
Frequency / duration: Once weekly for 46 weeks (20 weeks dose escalation)

Source wording: to subcutaneous survodutide (0·6, 2·4, 3·6, or 4·8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 386 (100%) participants were treated

le Roux CW, Steen O, Lucas KJ et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PubMed PMID 38330987 ↗

Human Adults with biopsy-confirmed MASH and fibrosis (293 dosed), phase 2 randomized trial

Dose as reported: 2.4, 4.8 or 6.0 mg (separate groups)
Route: Subcutaneous
Frequency / duration: Once weekly for 48 weeks

Source wording: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo.

Sanyal AJ, Bedossa P, Fraessdorf M et al.. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med 2024. PubMed PMID 38847460 ↗

Human Adults with type 2 diabetes, phase 2 randomized trial (placebo and open-label semaglutide comparators)

Dose as reported: Up to 0.3, 0.9, 1.8 or 2.7 mg once weekly; or 1.2 or 1.8 mg twice weekly (separate groups)
Route: Not stated in the abstract
Frequency / duration: Once or twice weekly

Source wording: Participants were randomised via interactive response technology to receive survodutide (up to 0.3, 0.9, 1.8 or 2.7 mg once weekly [qw; 1.2 or 1.8 mg twice weekly [DG 5 and 6, respectively]

Blüher M, Rosenstock J, Hoefler J et al.. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia 2024. PubMed PMID 38095657 ↗

Half-life

No half-life value was found in the sources reviewed for this page.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.